FGFR2 and cholangiocarcinoma: Actually, three small molecular inhibitors of FGFR2 including futibatinib [3,4], pemigatinib [5], and tasurgratinib [6] have been approved as of 2024 and are clinically used against cholangiocarcinoma with FGFR2 fusion genes in Japan.